Registered number: 04227738

Elysium Healthcare (Phoenix) Limited

Directors' report and financial statements

For the year ended 31 December 2018

FRIDAY



\*A8CZ5Y17\* A28 30/08/2019 COMPANIES HOUSE

#322

# **Company Information**

**Directors** Joy Chamberlain

Quazi Haque Steven Woolgar

Company secretary Sarah Livingston

Registered number 04227738

Registered office 2 Imperial Place

Maxwell Road Borehamwood Hertfordshire WD6 1JN United Kingdom

Auditor Deloitte LLP

**Statutory Auditor** 

London

United Kingdom

# Contents

	Page
Directors' annual report	1
Directors' responsibilities statement	3
Independent auditor's report	4
Profit and loss account	7
Balance sheet	8
Statement of changes in equity	g
Notes to the financial statements	10

# Directors' annual report For the year ended 31 December 2018

The Directors present their annual report and the audited financial statements for the year ended 31 December 2018.

#### **Directors**

The Directors who served during the year and up to the date of signing the financial statements were as follows:

Joy Chamberlain Quazi Haque Steven Woolgar Mark Robson (resigned 30 November 2018) Keith Browner (appointed 1 May 2019)

Keith Browner was appointed as a director of the Company following the end of the financial year.

#### **Directors' indemnities**

The Company has made qualifying third party indemnity provisions for the benefits of its directors which were made during the period and remain in force at the date of this report.

#### Impact of Brexit

Brexit is expected to have an immaterial impact on the Group's labour supply as the workforce does not contain a significant number of EU nationals. There does remain, however, continued uncertainty regarding changes to the UK's trading arrangements, customs agreements and tariffs post-Brexit. The Group has considered the impact of a potential Brexit scenario and understands the impact on the business to predominantly be an increased cost of food and pharmaceuticals expected to impact the industry as a whole. Any currency devaluation would further cause the costs of imported medical supplies to increase. Developments continue to be monitored.

## Going concern

As at 31 December 2018, the Company had net current liabilities of £3.4 million (2017: £2.2 million), net liabilities of £0.7 million (2017: assets of £0.2 million), and its loss for the year was £1.0 million (2017: profit of £0.0 million). The Company is part of a larger group, Elysium Healthcare Holdings 2 Limited (the "Group"), which has considerable financial resources, together with long-term contracts with a number of customers and suppliers across different geographical areas.

The Group meets its day to day working capital requirements through cash generated from operations and its borrowing facilities. The Group's forecasts and projections, taking account of reasonable possible changes in trading performance, show that the Group is able to operate within the level of its current facilities and meet its debt covenants.

After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the Directors' report and financial statements.

In addition to the above, the Company has received a letter of support from Elysium Healthcare Holdings 2 Limited.

# Directors' annual report (continued) For the year ended 31 December 2018

#### Disclosure of information to auditors

Each of the persons who is a Director at the date of approval of this report confirms that:

- so far as the Director is aware, there is no relevant audit information of which the Company's Auditor are unaware, and
- the Director has taken all the steps that he/she ought to have taken as a Director in order to make himself/herself aware of any relevant audit information and to establish that the Company's auditor are aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of Companies Act 2006.

Deloitte LLP has expressed their willingness to continue in office as auditor and appropriate arrangements have been put in place for them to be deemed reappointed as auditor in the absence of an Annual General Meeting.

This Directors' report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

This report was approved by the board on by:

16 MAY

2019 and signed on its behalf

Sarah Livingston Company secretary

# Directors' responsibilities statement For the year ended 31 December 2018

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

#### Independent auditor's report to the members of Elysium Healthcare (Phoenix) Limited

# Report on the audit of the financial statements Opinion

In our opinion the financial statements of Elysium Healthcare (Phoenix) Limited (the 'company'):

- give a true and fair view of the state of the company's affairs as at 31 December 2018 and of its loss] for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements which comprise:

- the profit and loss account:
- the balance sheet;
- the statement of changes in equity; and
- the related notes 1 to 12.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council's (the 'FRC's') Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Conclusions relating to going concern

We are required by ISAs (UK) to report in respect of the following matters where:

- the directors' use of the going concern basis of accounting in preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that
  may cast significant doubt about the company's ability to continue to adopt the going concern basis
  of accounting for a period of at least twelve months from the date when the financial statements are
  authorised for issue.

We have nothing to report in respect of these matters.

#### Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in respect of these matters.

#### Independent auditor's report to the members of Elysium Healthcare (Phoenix) Limited (continued)

## Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: <a href="https://www.frc.org.uk/auditorsresponsibilities">www.frc.org.uk/auditorsresponsibilities</a>. This description forms part of our auditor's report.

#### Report on other legal and regulatory requirements

### Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report has been prepared in accordance with applicable legal requirements.

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

#### Matters on which we are required to report by exception

Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- · certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the directors' report and from the requirement to prepare a strategic report.

We have nothing to report in respect of these matters.

## Independent auditor's report to the members of Elysium Healthcare (Phoenix) Limited (continued)

### Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Kate Davlison

Kate Darlison, FCA (Senior statutory auditor)
 For and on behalf of Deloitte LLP
 Statutory Auditor
 London
 United Kingdom

**2** May 2019

ſ,

# Profit and loss account For the Year ended 31 December 2018

Turnover	Note	Year ended 31 December 2018 £'000 679	Period ended 31 December 2017 £'000 1,657
Cost of sales		(1,043)	(1,423)
Gross (loss) / profit		(364)	234
Administrative expenses		(589)	(111)
Operating (loss) / profit		(953)	123
(Loss) / profit before taxation	2	(953)	123
Tax on (loss) / profit	4	(10)	(95)
(Loss) / profit for the year / period		(963)	28
Administrative expenses  Operating (loss) / profit  (Loss) / profit before taxation  Tax on (loss) / profit	•	(589) (953) (953) (10)	(111) 123 123 (95)

There were no recognised gains and losses for 2018 other than those included in the Profit and loss account.

The notes on pages 10 to 16 form part of these financial statements.

Registered number: 04227738

## Balance sheet As at 31 December 2018

2018 Note £'000	2017 £'000
Non-current assets	
Tangible fixed assets 5 2,771	2,571
Current assets	
Stocks 6 1	1
Debtors 7 5	565
Cash at bank and in hand 1	24
Creditors: amounts falling due within one year 8 (3,383)	(2,814)
Net current liabilities (3,376)	(2,224)
Total assets less current liabilities (605)	347
Provisions for liabilities 9 (108)	(98)
Net (liabilities) / assets (713)	249
Capital and reserves	
Called up share capital 1	1
Profit and loss account (714)	248
Shareholders' funds (713)	249

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements of Elysium Healthcare (Phoenix) Limited (registered number: 04227738) were approved by the board of directors and authorised for issue on /6 MAY 2019. They were signed on its behalf by:

Keith Browner Director

The notes on pages 10 to 16 form part of these financial statements.

# Statement of changes in equity As at 31 December 2018

	Called up share capital	Profit and loss account	Total shareholders' funds
	£'000	£'000	£'000
At 31 March 2017	1	220	221
Profit for the period	-	28	28
Dividends declared	<u> </u>		-
At 31 December 2017	1	248	249
Loss for the year	-	(963)	(963)
At 31 December 2018	. 1	(715)	(714)

# Notes to the financial statements For the year ended 31 December 2018

#### 1. Accounting Policies

# General information and basis of accounting

Elysium Healthcare (Phoenix) Limited (the 'Company') is a private company limited by shares incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is: 2 Imperial Place, Maxwell Road, Borehamwood, Hertfordshire WD6 1JN.

#### **Accounting policies**

The principal accounting policies are summarised below. They have all been applied consistently throughout the period.

### **Basis of preparation**

The financial statements have been prepared under the historical cost convention, as modified by the recognition of certain financial assets and liabilities measured at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued by the Financial Reporting Council. The functional currency of the Company is considered to be pounds sterling because that is the currency of the primary economic environment in which the Company operates. All amounts in these financial statements are presented in thousands of pounds Sterling (£'000), unless otherwise stated.

#### Going concern

As at 31 December 2018, the Company had net current liabilities of £3.4 million (2017: £2.2 million), net liabilities of £0.7 million (2017: assets of £0.2 million), and its loss for the year was £1.0 million (2017: profit of £0.0 million). The Company is part of a larger group, Elysium Healthcare Holdings 2 Limited (the "Group"), which has considerable financial resources, together with long-term contracts with a number of customers and suppliers across different geographical areas.

The Group meets its day to day working capital requirements through cash generated from operations and its borrowing facilities. The Group's forecasts and projections, taking account of reasonable possible changes in trading performance, show that the Group is able to operate within the level of its current facilities and meet its debt covenants.

After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the Directors' report and financial statements.

In addition to the above, the Company has received a letter of support from Elysium Healthcare Holdings 2 Limited.

#### **Turnover**

Turnover represents the supply of services including, bed fees, observation fees, training fees and is stated net of VAT, rebates and trade discounts and represents the value of services provided and delivered under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Turnover received in advance is included in deferred income until the service is provided. Turnover in respect of services provided but not yet invoiced by the period end is included within accrued income.

# Notes to the financial statements For the year ended 31 December 2018

# 1. Accounting Policies (continued)

### Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss.

For financial assets carried at amortised cost, the amount of impairment is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the financial asset's original effective interest rate.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

#### **Employee benefits**

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in the profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

#### **Taxation**

Current tax, including UK corporation tax and foreign tax, is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

A provision is recognised for those matters for which the tax determination is uncertain but it is considered probable that there will be a future outflow of funds to a tax authority. The provisions are measured at the best estimate of the amount expected to become payable. The assessment is based on specialist independent tax advice.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the balance sheet date. Timing differences are differences between the Company's taxable profits and its results as stated in the financial statements that arise from the inclusion of gains and losses in tax assessments in periods different from those in which they are recognised in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that, on the basis of all available evidence, it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date that are expected to apply to the reversal of the timing difference. In other cases, the measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current tax assets and liabilities are offset only when there is a legally enforceable right to set off the amounts and the Company intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

# Notes to the financial statements For the year ended 31 December 2018

## 1. Accounting Policies (continued)

Deferred tax assets and liabilities are offset only if: a) the Company has a legally enforceable right to set off current tax assets against current tax liabilities; and b) the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

### Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment.

Depreciation is recognised so as to write off the cost or valuation of assets (other than freehold land and properties under construction) less their residual values over their useful lives, using the straight-line method, on the following bases:

Freehold buildings 50 years
Plant and machinery 7 to 10 years
Motor vehicles 4 years
Fixtures and fittings 5 to 10 years
Computer equipment 3 to 7 years

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

#### **Stocks**

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.

# Notes to the financial statements For the year ended 31 December 2018

# 2. (Loss) /profit before taxation

(Loss) / profit before taxation is stated after charging:

	Year ended 31 December 2018 £'000	Period ended 31 December 2017 £'000
Depreciation of tangible fixed assets	94	81
Hire of plant and machinery	11	1
Fees payable to the Company's auditor for the audit of the Company's financial statements	4	4

# 3. Employees

The average monthly number of employees during the period was as follows:

Year ended 31 December 2018	Period ended 31 December 2017
28	34
5_	6
33	40
	31 December 2018 285

## 4. Taxation

	Year ended 31 December 2018 £'000	Period ended 31 December 2017 £'000
Corporation tax		
Current tax on (loss) / profit for the year / period	-	-
Adjustments to tax charge in respect of prior periods	-	
	<u>-</u>	-
Deferred tax		
Origination and reversal of timing differences	10	80
Adjustment to tax charge in respect of prior periods		
Total deferred tax	10	80
Tax on (loss) / profit	10	80

# Notes to the financial statements For the year ended 31 December 2018

## 4. Taxation (continued)

# Factors affecting tax charge for the year

The tax assessed for the year is the same as (June 2018: same as) the standard rate of corporation tax in the UK of 19% (June 2018: 19%). The differences are explained below:

(Loss) / profit before taxation	Year ended 31 December 2018 £'000 (963)	Period ended 31 December 2017 £'000 123
Profit multiplied by the standard rate of corporation tax in the UK of 19% (June 2018: - 19%)	(183)	23
Effects of:		
Fixed asset differences	11	9
Group relief surrendered	180	-
Expenses not deductible for tax	1	-
Adjustment to changes to tax rates	-	(3)
Other differences	1	51
Tax on (loss) / profit	10	80

## Factors that may affect future tax charges

The level of disallowable expenses and utilisation of tax losses carried forward will impact future tax charges.

A change to the UK corporation tax rate was announced in the Chancellor's Budget on 16 March 2016. The change was to reduce the main rate to 17% from 1 April 2020. The change to 17% from 1 April 2020 had been substantively enacted at the balance sheet date so its effects are included in these financial statements and the Company's deferred tax balances have been restated to reflect their expected unwind at 17%.

### 5. Tangible fixed assets

Cost	Land and buildings £'000	Fixtures, fittings and equipment £'000	Total £'000
At 1 January 2018	3,094	525	3,619
Additions	248	46	294
At 31 December 2018	3,342	571	3,913
Depreciation			
At 1 January 2018	583	465	1,048
Charge for the period	58_	36	94
At 31 December 2018	641	501_	1,142

# Notes to the financial statements For the year ended 31 December 2018

# 5. Tangible fixed assets (continued)

	Land and buildings £'000	fi: equip	tures, ttings and oment £'000	Total £'000
Net book value At 31 December 2018	2,701		70	2,771
At 31 December 2017	2,511		60	2,571
6. Stocks				
	Year 31 Dec	ended ember 2018 £'000		Period ended 31 December 2017 £'000
Food, pharmaceuticals and other consumables		1	_	1
7. Debtors				
	Year 31 Dec	ended ember 2018 £'000		Period ended 31 December 2017 £'000
Amounts falling due within one year:		2000		2 000
Trade debtors		-		559
Prepayments and accrued income		<u>5</u> 5	- =	6 565
8. Creditors: Amounts falling due within one year				
		r ended cember 2018 £'000		Period ended 31 December 2017 £'000
Trade creditors		16		29
Other taxation and social security		-		8
Other creditors		4		2
Amounts owed to group undertakings		3,317		2,645
Accruals and deferred income		46		129
		3,383	: :	2,814

Amounts owed to group undertakings due within one year are unsecured, non-interest bearing and repayable on demand.

# Notes to the financial statements For the year ended 31 December 2018

#### 9. Provisions for liabilities

		Deferred tax £'000
At 1 January 2018 Charged to profit or loss		98 10
Period ended 31 December 2018		108
The provision for deferred taxation is made up as	follows:	
Accelerated capital allowances	Year ended 31 December 2018 £'000 98	Period ended 31 December 2017 £'000 98
Tax losses carried forward	10 108	98

#### 10. Pensions commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £8,848 (31 December 2017: £5,754). Contributions totalling £nil (31 December 2017: £2,691) were payable to the fund at the balance sheet date and are included in other creditors.

### 11. Subsequent events

There were no adjusting or non-adjusting events occurring between the end of the reporting period and the date these financial statements were approved.

### 12. Controlling party

The immediate parent undertaking is Elysium Healthcare (Lighthouse) Limited, with registered office at 2 Imperial Place, Maxwell Road, Borehamwood, Hertfordshire WD6 1JN.

The ultimate parent undertaking is P Health S.A.R.L., a Company incorporated in Luxembourg with registered address at 29 Avenue de la Porte Neuve, L-2227 Luxembourg, RCS Luxembourg, B 194.610 which is controlled by funds advised by BC Partners LLP.

At the year end the largest group in which the results of the Company are consolidated is that headed by Elysium Healthcare Holdings 1 Limited, incorporated in England and Wales. The smallest group in which the results of the Company are consolidated is that headed by Elysium Healthcare Holdings 2 Limited, incorporated in England and Wales. The address of the registered office of Elysium Healthcare Holdings 1 Limited and Elysium Healthcare Holdings 2 Limited is: 2 Imperial Place, Maxwell Road, Borehamwood, Hertfordshire WD6 1JN, where the consolidated financial statements of the Elysium Healthcare Holdings 1 Limited group and the Elysium Healthcare Holdings 2 Limited group may be obtained.